BR112014006124A2 - dosagem faseada de clopidogrel - Google Patents

dosagem faseada de clopidogrel

Info

Publication number
BR112014006124A2
BR112014006124A2 BR112014006124A BR112014006124A BR112014006124A2 BR 112014006124 A2 BR112014006124 A2 BR 112014006124A2 BR 112014006124 A BR112014006124 A BR 112014006124A BR 112014006124 A BR112014006124 A BR 112014006124A BR 112014006124 A2 BR112014006124 A2 BR 112014006124A2
Authority
BR
Brazil
Prior art keywords
clopidogrel
staged
dosage
phased
stroke
Prior art date
Application number
BR112014006124A
Other languages
English (en)
Inventor
R Plachetka John
Original Assignee
Pozen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pozen Inc filed Critical Pozen Inc
Publication of BR112014006124A2 publication Critical patent/BR112014006124A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

phased dosing of clopidogrel abstract the present invention provides for novel formulations of clopidogrel to provide for phased/spaced release for use as improved antiplatelet therapies in stroke and cardiovascular indications. ____________________ tradução do resumo resumo patente de invenção: "dosagem faseada de clopidogrel". a presente invenção proporciona novas formulações de clopidogrel para fornecer liberação faseada / espaçada para uso como terapias antiplaquetárias melhoradas em acidente vascular cerebral e indicações cardiovasculares.
BR112014006124A 2011-09-14 2012-09-14 dosagem faseada de clopidogrel BR112014006124A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161534648P 2011-09-14 2011-09-14
PCT/US2012/055550 WO2013040442A1 (en) 2011-09-14 2012-09-14 Phased dosing of clopidogrel

Publications (1)

Publication Number Publication Date
BR112014006124A2 true BR112014006124A2 (pt) 2017-04-11

Family

ID=47883794

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014006124A BR112014006124A2 (pt) 2011-09-14 2012-09-14 dosagem faseada de clopidogrel

Country Status (8)

Country Link
US (1) US20150024042A1 (pt)
EP (1) EP2755979A4 (pt)
CN (1) CN103917544A (pt)
BR (1) BR112014006124A2 (pt)
CA (1) CA2848756A1 (pt)
EA (1) EA201490626A1 (pt)
MX (1) MX2014003214A (pt)
WO (1) WO2013040442A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105218559A (zh) * 2015-10-21 2016-01-06 云南省药物研究所 一种稳定的非晶态硫酸氢氯吡格雷复合物
CN115980223A (zh) * 2022-12-29 2023-04-18 大连博源医学科技有限公司 一种用于检测血液中11-脱氢血栓烷b2的液相色谱-串联质谱方法和试剂盒

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7029701B2 (en) * 2000-09-11 2006-04-18 Andrx Pharmaceuticals, Llc Composition for the treatment and prevention of ischemic events
US20060210633A1 (en) * 2003-04-03 2006-09-21 Sun Pharmaceutical Industries Limited Programmed drug delivery system
US20060280795A1 (en) * 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
MX2007015882A (es) * 2005-06-13 2008-03-04 Elan Pharma Int Ltd Formulaciones en combinacion nanoparticulada de clopidogrel y aspirina.
FR2887455B1 (fr) * 2005-06-28 2007-08-10 Sanofi Aventis Sa Formulation a liberation prolongee de principes actifs de medicaments
MX349787B (es) * 2006-04-04 2017-08-11 Kg Acquisition Llc Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
JP2009532462A (ja) * 2006-04-05 2009-09-10 カディラ・ヘルスケア・リミテッド 調節放出クロピドグレル製剤
WO2007122636A1 (en) * 2006-04-25 2007-11-01 Panacea Biotec Ltd Pharmaceutical compositions containing long chain fatty acids as excipients as well as a process for manufacturing the same
WO2009104932A2 (ko) * 2008-02-22 2009-08-27 한올제약주식회사 복합제제
CN101703513B (zh) * 2009-11-10 2014-04-23 沈阳药科大学 阿司匹林和氯吡格雷或其药学上可接受的盐的复方缓释制剂
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery

Also Published As

Publication number Publication date
EA201490626A1 (ru) 2014-08-29
CA2848756A1 (en) 2013-03-21
MX2014003214A (es) 2014-12-05
CN103917544A (zh) 2014-07-09
EP2755979A1 (en) 2014-07-23
WO2013040442A1 (en) 2013-03-21
US20150024042A1 (en) 2015-01-22
EP2755979A4 (en) 2015-06-17

Similar Documents

Publication Publication Date Title
IL265707A (en) Pharmaceutical preparations containing human antibodies to pcsk9
CL2014001291A1 (es) Agentes de iarn de doble hebra; composiciones y metodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr).
IL236892B (en) A combination of an immunoconjugate and an antibody for use in medical treatment, a pharmaceutical preparation and a kit containing it
CO6920258A2 (es) Proteínas de función dual para tratar trastornos metabólicos
CO6940374A2 (es) Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas
IL239355A0 (en) Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders
BR112014031310A2 (pt) anticorpos anti-pcsk9, formulações, dosagem e métodos de uso
CL2013002123A1 (es) Composicion herbicida que comprende topramezona y pinoxaden; uso de dicha composicion para controlar vegetación indeseable; formulación indeseable.
EP3016715A4 (en) Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy
GB201215917D0 (en) Improvements in or relating to dose indicators
BR112014017481A8 (pt) formulação em pó seco para uso em um inalador de pó seco, inalador de pó seco e uso de uma formulação
BR112014011724A2 (pt) composição de barra de sabão e barra de sabão
UY34078A (es) Composiciones farmacéuticas y métodos para tratar el cáncer
IL237139A0 (en) Pharmaceutical compositions of memantine
PL2861618T3 (pl) BAG3 jako surowiczy i tkankowy marker biochemiczny
BR112014026326A2 (pt) composição para tratamento de distúrbios metabólicos
SG10201609119VA (en) Novel dosage form and formulation of abediterol
BR112014006124A2 (pt) dosagem faseada de clopidogrel
AU343311S (en) Note dispenser
EP2801365A4 (en) USE OF DANSHEN OR A DANSHENE PREPARATION IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH LIVER FIBROSIS
FR3005407B1 (fr) Kit a usage unique pour la preparation de principes actifs par dissolution et/ou chauffage
BR112013025604A2 (pt) uso de uma preparação na fabricação de uma composição nutricional líquida, composição nutricional líquida e uso da composição nutricional líquida
DK2874611T3 (da) Gastroresistent farmaceutisk formulering med forsinket frigivelse
AU343310S (en) Note dispenser
AU344415S (en) Note dispenser

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]